Insights
Insights From Our Experts
Articles
Successfully Navigating Global Commercialization- A View from the C-Suite and Global Commercial Leaders
Launching in today’s unpredictable market is a journey with new challenges around every corner. While product pipelines are rapidly growing, stringent competition and an evolving provider environment are putting intense pressure on manufacturers to build…
Insight from Frontiers Health: Harnessing Machine Learning to Transform Clinical Outcomes
Our Chief Medical Officer, Dr. Pierantonio Russo, joined on stage at Frontiers Health 2024 to discuss the impact of Machine Learning (ML) on healthcare, particularly in predicting hospital readmissions and managing chronic diseases. In this session,…
The Promise of Direct-to-Patient – What’s Really Needed for Patient Access
In today’s healthcare landscape, patients are no longer passive recipients of care. They are empowered, tech-savvy stakeholders who demand efficiency and transparency. Yet, despite advancements in consumer innovation, the healthcare system often leaves them frustrated with…
The Importance of Quality-of-Life Metrics in mCRPC
Posted by
Rhett Figliuzzi , Samantha Craigie , Sarah Walsh , Imtiaz Samjoo on November 26, 202411/26/24
Prostate cancer is one of the most diagnosed malignancies in the world, with many patients progressing to an advanced stage of the disease called metastatic castration-resistant prostate cancer (mCRPC). Due to the poor prognosis and incurable…
The Increasing Role of AI in Improving the Diagnostic Imaging Landscape
Discover how artificial intelligence is revolutionizing the medical imaging landscape in our latest white paper, “The Increasing Role of AI in Improving the Diagnostic Imaging Landscape.” This comprehensive guide explores: Enhanced Diagnostic Accuracy: Learn how AI…
A Review of Indirect Treatment Comparisons (ITCs) in Regulatory Approval, Reimbursement and Pricing Recommendations for Oncology Drugs
Posted by
Krista Tantakoun , Christopher Olsen , Fatemeh Mirzayeh Fashami , Imtiaz Samjoo , Chris Cameron, PhD on November 19, 202411/19/24
The use of indirect treatment comparisons (ITCs) has increased significantly in recent years, particularly in the assessment of oncology and rare diseases where direct head-to-head trials may be impractical or unavailable, with numerous oncology and orphan…
Insights from SAHARA+ Conference: Harnessing Real-World Data and AI to Transform Healthcare
EVERSANA’s executive director and Middle East head, Prashant Pandarathil, recently presented at Saudi Arabia’s Healthcare Advancement for Resourceful Funding, Regulatory Excellence and Innovation (SAHARA+) Conference on the topic “Harnessing the Power of Real-World Data (RWD) and…
Finding the Human Element Amid the Algorithms
Posted on November 12, 202411/12/24
The programmatic buying and selling of health media is, ultimately, steered by the humans that enable it. So why does the notion that it’s a machine-driven process still linger? Spend more than a few minutes of…
Adherence Redefined: Evolving Approaches to Adherence in Oncology Clinical Pathways
Discover how leading cancer institutions are redefining adherence to clinical pathways. Our latest white paper, “Adherence Redefined: Evolving Approaches to Adherence in Oncology Clinical Pathways,” authored by EVERSANA MANAGEMENT CONSULTING, delves into the shifting landscape of oncology…
Comparing First-Line Treatments for mCRPC: Insights From a Comprehensive NMA
Posted by
Imtiaz Samjoo , Jenna Ellis , Samantha Craigie , Anja Haltner, MSc on November 4, 202411/4/24
Several first-line (1L) pharmacological treatments are available for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC), an incurable condition with poor prognosis and quality of life. Benefits to patient survival in clinical trials have…